Canaccord Genuity Rates Rhythm Pharmaceuticals (RYTM) buy
The firm sets a price target of $151 for Rhythm Pharmaceuticals, indicating potential upside from the current trading price.
Reviewed by automated data checks against the source data. How we make and check alerts
Canaccord Genuity rated Rhythm Pharmaceuticals, Inc. ($RYTM) "buy" with a $151 price target on June 16, 2026.
Since the rating, $RYTM is up 18.4% after 1 week, up 18.2% after 1 month and down 4.0% to date (from the $89.72 close on Jun 16, 2026).
RYTM
Rhythm Pharmaceuticals, Inc.
Key Points
- Canaccord Genuity reiterated its buy rating on Rhythm Pharmaceuticals, Inc. with a price target of $151 on June 16, 2026.
- The stock is currently trading at $101.39, which is significantly below the analyst's target, suggesting potential upside.
- With a market cap of approximately $6.8 billion, Rhythm Pharmaceuticals focuses on treatments for rare neuroendocrine diseases.
Get $RYTM trade alerts by text
We text you when insiders, Congress or big funds trade $RYTM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Rhythm Pharmaceuticals, Inc. alert may contain errors. Disclosures
Canaccord Genuity's Buy Rating
On June 16, 2026, Canaccord Genuity reiterated its buy rating on Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM) and set a price target of $151. The stock is currently trading at $101.39, which is well below the target price, indicating potential for upside based on the firm's assessment.
Analysts Set New Price Targets
This reiteration comes as part of a broader positive sentiment around Rhythm Pharmaceuticals. The stock has seen interest from other analysts as well. For instance, on October 16, 2026, William Blair initiated coverage with an Outperform rating. JP Morgan has maintained its Overweight rating with a target of $145.0 as of October 15, 2026, while HC Wainwright & Co. also holds a Buy rating with a target of $130.0. RBC Capital has been optimistic too, maintaining an Outperform rating with a target of $159.0. This collective support from various firms adds to the confidence in Rhythm’s future.
How Rhythm Pharmaceuticals, Inc. Stock Has Traded
Rhythm Pharmaceuticals trades at $101.39, which is above its 50-day moving average of $107.16 but below its 52-week high of $122.20. The stock's current price compared to the target set by Canaccord Genuity suggests that investors might see significant upside if the company meets its growth expectations.
$RYTM price target
Rhythm Pharmaceuticals, Inc. daily closes and this analyst's $151 target. Not advice.
What Rhythm Pharmaceuticals, Inc. Does
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts. It specializes in developing treatments for rare neuroendocrine diseases. Its lead product candidate, IMCIVREE, is aimed at treating various genetic obesity syndromes. The company's focus on niche markets positions it uniquely within the healthcare sector.
What’s Next for Rhythm Pharmaceuticals
Investors will be watching closely as Rhythm Pharmaceuticals prepares for its next earnings report on November 3, 2026. The upcoming earnings call may provide insights into the company's progress and any updates on its clinical trials. Remember, the 13F filings reflect past holdings and may not represent current positions, so keeping an eye on future filings will be essential.
Related Filing Alerts
Source: Canaccord Genuity's rating change on $RYTM (Jun 16, 2026). Written by software, not financial advice. How we make alerts